KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) Equity Average (2016 - 2025)

Historic Equity Average for Resmed (RMD) over the last 16 years, with Q4 2025 value amounting to $6.2 billion.

  • Resmed's Equity Average rose 1908.6% to $6.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 billion, marking a year-over-year increase of 1908.6%. This contributed to the annual value of $5.4 billion for FY2025, which is 2043.55% up from last year.
  • Latest data reveals that Resmed reported Equity Average of $6.2 billion as of Q4 2025, which was up 1908.6% from $6.0 billion recorded in Q3 2025.
  • Resmed's 5-year Equity Average high stood at $6.2 billion for Q4 2025, and its period low was $2.8 billion during Q1 2021.
  • In the last 5 years, Resmed's Equity Average had a median value of $4.1 billion in 2023 and averaged $4.2 billion.
  • Examining YoY changes over the last 5 years, Resmed's Equity Average showed a top increase of 2347.26% in 2021 and a maximum decrease of 1132.86% in 2021.
  • Resmed's Equity Average (Quarter) stood at $3.1 billion in 2021, then increased by 16.19% to $3.6 billion in 2022, then grew by 21.77% to $4.4 billion in 2023, then rose by 19.65% to $5.2 billion in 2024, then rose by 19.09% to $6.2 billion in 2025.
  • Its Equity Average stands at $6.2 billion for Q4 2025, versus $6.0 billion for Q3 2025 and $5.8 billion for Q2 2025.